Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Rafabegron
Cat. No.:
OB0425LY-075
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
Rafabegron is a specific agonist of beta3-adrenoceptor has the ability to stimulate the breakdown of adipose tissue and increase energy expenditure.
Synonyms:
244081-42-3; AJ-9677; TAK-677; 2-((3-((R)-2-(((R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yl)oxy)acetic acid
CAS No.:
244081-42-3
Compound CID:
5493324
Formula:
C21H23ClN2O4
Formula Weight:
402.87
Specification
Target:
Adrenergic receptor
Pathway:
GPCR/G protein; Neuronal signaling
Storage:
Storage at -20°C.
Applications:
Rafabegron is mainly used in studies for the treatment of obesity and related metabolic syndromes, and is beneficial in improving insulin sensitivity and metabolic status.
